IP Library › Granted Patent US 10,213,390
Granted Patent B1
US 10,213,390 · App. 16/144,632 · Granted Feb 26, 2019

Treatment of fragile X syndrome with cannabidiol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,213,390
App. No.
16/144,632
Granted
Feb 26, 2019
Kind
B1
Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Claims (9)

1. A method of treating a human suffering from Fragile X Syndrome comprising:

administering a therapeutically effective amount of synthetic or purified cannabidiol to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.

2. The method of claim 1 , wherein the cannabidiol is (−)-cannabidiol.

3. The method of claim 1 , wherein the effective amount of cannabidiol is between about 50 mg and about 500 mg total daily.

4. The method of claim 1 , wherein the cannabidiol is formulated as a gel.

5. The method of claim 4 , wherein the cannabidiol is formulated as a permeation-enhanced gel.

6. The method of claim 1 , wherein the cannabidiol is administered in a single daily dose.

7. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.

8. The method of claim 1 , wherein the cannabidiol is transdermally administered.

Assignments (3)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2020
From: SEBREE, TERRI; BONN-MILLER, MARCEL; TICH, NANCY; MESSENHEIMER, JOHN; GUTTERMAN, DONNA
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 053700/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: BONN-MILLER, MARCEL; TICH, NANCY; GUTTERMAN, DONNA; MESSENHEIMER, JOHN; SEBREE, TERRI
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 047032/0578 →
Cited By (8)
US 12,186,280 US 12,186,282 US 12,213,951 US 12,226,373 US 12,268,699 US 12,409,131 US 12,409,132 US 12,582,664